Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

The Long Run with Luke Timmerman by The Long Run with Luke Timmerman

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).